Pharmacokinetics for regulatory risk analysis: The case of trichloroethylene

doi:10.1016/0273-2300(88)90045-1

Regulatory Toxicology and Pharmacology

Volume 8, Issue 4, December 1988, Pages 447-466

https://doi.org/10.1016/0273-2300(88)90045-1 Get rights and content

Abstract

Physiologically based pharmacokinetic (PBPK) models describing the uptake, metabolism, and excretion of volatile organic compounds (VOCs) are now proposed for use in regulatory health-risk assessment. A steady-state analysis of one such model is shown to provide simple, convenient predicted relationships between an applied dose and the corresponding toxicologically effective, metabolized dose for certain VOCs like trichloroethylene (TCE). A version of this PBPK model was fit to data on human metabolism of TCE to urinary metabolites in chronically exposed workers, yielding a direct estimate of PBPK parameters governing human capacity to metabolize TCE. It is shown that this estimate is consistent with others based on experimental studies of TCE metabolism in humans exposed to TCE by inhalation for short periods. These results are applied to human cancer-risk assessment using rodent bioassay data on TCE-induced tumorigenesis.

References (49)

M.E. Andersen et al.
Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements
Toxicol. Appl. Pharmacol.
(1980)
M.E. Andersen
A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: Analysis at steady state
Toxicol. Appl. Pharmacol.
(1981)
M.E. Andersen et al.
Physiologically based pharmacokinetics and the risk assessment process for methylene chloride
Toxicol. Appl. Pharmacol.
(1987)
J.A. Buben et al.
Delineation of the role of metabolism in the hepatotoxicity of trichloroethylene and perchloroethylene: A dose-effect study
Toxicol. Appl. Pharmacol.
(1985)
M.L. Gargas et al.
Metabolism of inhaled dihalomethanes in vivo: Differentiation of kinetic constants for two independent pathways
Toxicol. Appl. Pharmacol.
(1986)
P.J. Gehring et al.
Resolution of dose-response toxicity data for chemicals requiring metabolic activation: Example—Vinyl chloride
Toxicol. Appl. Pharmacol.
(1978)
T. Green et al.
Species differences in response to trichloroethylene. II. Biotransformation in rats and mice
Toxicol. Appl. Pharmacol.
(1985)
M.S. Prout et al.
Species differences in response to trichloroethylene: Pharmacokinetics in rats and mice
Toxicol. Appl. Pharmacol.
(1985)
J.C. Ramsey et al.
A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans
Toxicol. Appl. Pharmacol.
(1984)
W.T. Stott et al.
Pharmacokinetics and macromolecular interactions of trichloroethylene in mice and rats
Toxicol. Appl. Pharmacol.
(1982)

R.C. Ward et al.

Pharmacokinetics of tetrachlorethylene

J. Toxicol. Appl. Pharmacol.

(1988)

E.L. Anderson et al.

Quantitative approaches in use to assess cancer risk

Risk anal.

(1983)

V.J. Bartonicek

Metabolism and excretion of trichloroethylene after inhalation by human subjects

Brit. J. Ind. Med.

(1962)

Z.G. Bell et al.

Final Report of Audit Findings of the Manufacturing Chemists Association (MCA): Administered Trichloroethylene (TCE) Chronic Inhalation Study at Industrial Bio-TestLaboratories, Inc., Decatur, Illinois

(1978)

K.T. Bogen et al.

Linking indoor air and pharmacokinetic models to assess tetrachloroethylene risk

Risk Anal.

(1987)

K.T. Bogen et al.

Health Risk Assessment of Trichloroethylene (TCE) in California Drinking Water

E.J. Calabrese

K.S. Crump et al.

The multistage model with a time-dependent dose pattern: Applications to carcinogenic risk assessment

Risk Anal.

(1984)

K.S. Crump et al.

R.L. Dedrick et al.

Species similarities in pharmacokinetics

T. Ertle et al.

Metabolism of trichloroethylene in man. I. The significance of trichloroethanol in long-term exposure conditions

Arch. Toxicol.

(1972)

J.G. Fernandez et al.

Exposition au trichloroethylene: Bilan de l'absorption, de l'excretion et du metabolisme sur des sujets humains

Arch. Mal. Prof. Med. Trav. Secur. Soc. (Paris)

(1975)

J.G. Fernandez et al.

Trichloroethylene exposure simulation of uptake, excretion, and metabolism using a mathematical model

Brit. J. Ind. Med.

(1977)

K. Fukuda et al.

Inhalation carcinogenicity of trichloroethylene in mice and rats

Ind. Health

(1983)

Cited by (41)

Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants
2013, Regulatory Toxicology and Pharmacology
The objective of this study was to evaluate the impact of interindividual differences in hepatic first-pass effect (FPE) on the magnitude of the human kinetic adjustment factor (HKAF) for ingested toxicants. This factor aims at replacing a default value of 3.2 used in non-cancer risk assessment. Coupled with Monte Carlo simulations, steady-state equations that account for FPE were used to obtain distributions of arterial blood concentrations (CAss) and rates of metabolism in adults, neonates, infants and toddlers continuously exposed to an oral dose of 1 μg/kg/d of theoretical CYP2E1 and CYP1A2 substrates. For such substrates exhibiting a range of blood:air partition coefficients (Pb: 1–10,000) and hepatic extraction ratios in an average adult (E_ad: 0.01–0.99), HKAFs were computed as the ratio of the 95th percentile of dose metrics for each subpopulation over the 50th percentile value in adults. The reduced hepatic enzyme content in neonates as compared to adults resulted in correspondingly diminished FPE. Consequently, HKAFs greater than 3.2 could be observed, based on CAss only, in the following cases: for some CYP2E1 substrates with E_ad ⩽ 0.3, in neonates (max.: 6.3); and for some CYP1A2 substrates with E_ad ⩽ 0.1 and 0.7, in, respectively, neonates and infants (max.: 28.3). Overall, this study pointed out the importance of accounting for child/adult differences in FPE when determining the HKAF for oral exposure.
Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach
2007, Regulatory Toxicology and Pharmacology
The derivation of reference concentrations (RfCs) for systemically acting volatile organic chemicals (VOCs) uses a default factor of 10 to account for the interindividual variability in pharmacokinetics (PK) and pharmacodynamics (PD). The magnitude of the PK component of the interindividual variability factor (IVF; also referred to as human kinetic adjustment factor (HKAF)) has previously been estimated using Monte Carlo approaches and physiologically based pharmacokinetic (PBPK) models. Since the RfC derivation considers continuous lifetime human exposure to VOCs in the environment, algorithms to compute steady-state internal dose (SS-ID), such as steady-state arterial blood concentration (Ca) and the steady-state rate of amount metabolized (RAM), can be used to derive IVF-PKs. In this context, probability-bounds (P-bounds) approach is potentially useful for computing an interval of probability distribution of SS-ID from knowledge of population distribution of input parameters. The objective of this study was therefore to compute IVF-PK using the P-bounds approach along with an algorithm for SS-ID in an adult population exposed to VOCs. The existing steady-state algorithms, derived from PBPK models, were rewritten such that SS-ID could be related, without any interdependence, to the following input parameters: alveolar ventilation (Qp), hepatic blood flow (Ql), intrinsic clearance (CL_int) and blood:air partition coefficient (Pb). The IVF-PK was calculated from the P-bounds of SS-ID corresponding to the 50th and 95th percentiles. Following either specification of probability distribution-free bounds (characterized by minimal, maximal, and mean values) or distribution-defined values (mean, standard deviation and shape of probability distribution where: Qp = lognormal, Ql = lognormal, CL_int = lognormal and Pb = normal) in RAMAS Risk Calc^® software version 3.0 (Applied Biomathematics, Setauket, NY), the P-bound estimates of SS-ID for benzene, carbon tetrachloride, chloroform and methyl chloroform were obtained for low level exposures (1 ppm). Using probability distribution-defined inputs, the IVF-PK for benzene, carbon tetrachloride, chloroform and methyl chloroform were, respectively, 1.18, 1.28, 1.24, and 1.18 (based on P-bounds for Ca), and 1.31, 1.58, 1.30, and 1.24 (based on P-bounds for RAM). A validation of the P-bounds computation was performed by comparing the results with those obtained using Monte Carlo simulation of the steady-state algorithms. In data-poor situations, when the statistical distributions for all input parameters were not known or available, the P-bounds approach allowed the estimation of IVF-PK. The use of P-bounds method along with steady-state algorithms, as done in this study for the first time, is a practical and scientifically sound way of computing IVF-PKs for systemically acting VOCs.
A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice
1997, Toxicology and Applied Pharmacology
A six-compartment physiologically based pharmacokinetic (PBPK) model for the B6C3F1 mouse was developed for trichloroethylene (TCE) and was linked with five metabolite submodels consisting of four compartments each. The PBPK model for TCE and the metabolite submodels described oral uptake and metabolism of TCE to chloral hydrate (CH). CH was further metabolized to trichloroethanol (TCOH) and trichloroacetic acid (TCA). TCA was excreted in urine and, to a lesser degree, metabolized to dichloroacetic acid (DCA). DCA was further metabolized. The majority of TCOH was glucuronidated (TCOG) and excreted in the urine and feces. TCOH was also excreted in urine or converted back to CH. Partition coefficient (PC) values for TCE were determined by vial equilibrium, and PC values for nonvolatile metabolites were determined by centrifugation. The largest PC values for TCE were the fat/blood (36.4) and the blood/air (15.9) values. Tissue/blood PC values for the water-soluble metabolites were low, with all PC values under 2.0. Mice were given bolus oral doses of 300, 600, 1200, and 2000 mg/kg TCE dissolved in corn oil. At various time points, mice were sacrificed, and blood, liver, lung, fat, and urine were collected and assayed for TCE and metabolites. The 1200 mg/kg dose group was used to calibrate the PBPK model for TCE and its metabolites. Urinary excretion rate constant values were 0.06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1.55/hr/kg for TCA. A fecal excretion rate constant value for TCOG was 4.61/hr/kg. For oral bolus dosing of TCE with 300, 600, and 2000 mg/kg, model predictions of TCE and several metabolites were in general agreement with observations. This PBPK model for TCE and metabolites is the most comprehensive PBPK model constructed for P450-mediated metabolism of TCE in the B6C3F1 mouse.
Trichloroethylene cancer risk: Simplified calculation of PBPK-Based MCLs for cytotoxic end points
1997, Regulatory Toxicology and Pharmacology
Cancer risk assessments for trichloroethylene (TCE) based on linear extrapolation from bioassay results are questionable in light of new data on TCE's likely mechanism of action involving induced cytotoxicity, for which a threshold-type dose–response model may be more appropriate. Previous studies have shown that if a genotoxic mechanism for TCE is assumed, algebraic methods can considerably simplify the use of physiologically based pharmacokinetic (PBPK) models to estimate virtually safe environmental concentrations for humans based on rodent cancer-bioassay data. We show here how such methods can be extended to the case in which TCE is assumed to induce cancer via cytotoxicity, to estimate environmentally safe concentrations based on rodent toxicity data. These methods can be substituted for the numerical methods typically used to calculate PBPK-effective doses when these are defined as peak concentrations. We selected liver and kidney as plausible target tissues, based on an analysis of rodent TCE-bioassay data and on a review of related data bearing on mechanism. Tumor patterns in rodent bioassays are shown to be consistent with our estimates of PBPK-based, effective cytotoxic doses to mice and rats used in these studies. When used with a margin of exposure of 1000, our method yielded maximum concentration levels for TCE of 16 ppb (87 μg/m³) for TCE in air respired 24 hr/day, 700 ppb (3.8 mg/m³) for TCE in air respired for relatively brief daily periods (e.g., 0.5 hr while showering/bathing), and 210 μg/liter for TCE in drinking water assuming a daily 2-liter ingestion. Cytotoxic effective doses were also estimated for occupational respiratory exposures. These estimates indicate that the current OSHA permissible exposure limit for TCE would produce metabolite concentrations that exceed anacuteno observed adverse effect level for hepatotoxicity in mice. On this basis, the OSHA TCE limit is not expected to be protective.
The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances
1995, Toxicology Letters
Physiologically based pharmacokinetic (PBPK) modeling is an important tool for improving the accuracy of human health risk assessments for hazardous substances in the environment. The proper use of PBPK modeling can reduce uncertainties that currently exist in risk assessment procedures by providing more scientifically credible extrapolations across species and routes of exposure, and from high experimental doses to potential environmental exposures. Current applications of PBPK models range from relatively straightforward uses for the extrapolation of chemical kinetics across species, route, and duration of exposure to much more demanding chemical risk assessment applications requiring a description of complex pharmacodynamic phenomena such as mitogenicity and hyperplasia secondary to cytotoxicity. PBPK modeling helps to identify the factors that are most important in determining the health risks associated with exposure to a chemical, and provides a means for estimating the impact of those factors both on the average risk to a population and on the specific risk to an individual. The chief challenge in the application of PBPK modeling in human health risk assessment lies in the need to generate chemical-specific data to support the development and validation of the models. Extensive use of rapidly developing in vitro and structure-activity relationship techniques is needed to provide the data required for the large number of hazardous chemicals currently contaminating the environment.
Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances
1995, Toxicology Letters
Recent advances in physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) modeling have introduced novel approaches for evaluating toxicological problems. Because PBPK models are amenable to extrapolation of tissue dosimetry, they are increasingly being applied to chemical risk assessment. A comprehensive listing of PBPK/PD models for environmental chemicals developed to date is referenced. Salient applications of PBPK/PD modeling to health risk assessments and characterization of hazardous substances are illustrated with examples.

View all citing articles on Scopus

View full text